.png){kind=logo}
Anthropic has acquired Coefficient Bio in a stock deal worth about $400 million. The New York-based Biotech AI Startup had largely operated in stealth mode and was known for building biology-focused AI tools for drug discovery and scientific research.
The acquisition gives Anthropic a stronger foothold in healthcare and life sciences. The organization has used Claude to expand steadily in these two sectors. Coefficient Bio reportedly developed AI systems that could support biotech tasks such as drug R&D planning, clinical regulatory strategy, and identifying new drug candidates.
The deal is relatively small compared to Anthropic’s massive valuation. However, it could have an outsized impact on the company’s ability to build advanced AI tools for biology and medicine.
Coefficient Bio was founded by Samuel Stanton and Nathan C. Frey. Both of the founders have previously worked at Prescient Design, the Genentech Computational Biology unit focused on AI-driven drug discovery.
Stanton has a background in machine learning, experimental design, and drug discovery research. He contributed to several scientific AI projects during his time at Genentech.
Frey possesses extensive knowledge about biological base models, biomolecule development, and artificial intelligence planning. At Genentech, he directed teams that combined machine learning with engineering and molecular biology fields. He has published over 20 research papers and received the 2026 Termeer Fellow award.
The deal highlights a broader trend. Genentech talent moving into AI-native biotech companies. Startups such as Xaira Therapeutics have also attracted former Genentech researchers and executives.
The Coefficient Bio team is expected to join Anthropic’s healthcare and life sciences division. The company works to make Claude one of the leading AI models for biology and drug discovery.
Anthropic’s latest move shows that competition in AI-powered biotech research is only getting stronger.
The acquisition of Coefficient Bio by Anthropic showcases the intention to develop advanced artificial intelligence systems for scientific research purposes. The acquisition enhances the company's talent resources and specialized knowledge base. This plays a vital role in advancing biotechnology research.
The scientific competition between Xaira Therapeutics and its competitors will transition from evaluating model performance to assessing actual scientific results. Anthropic will become a major force in AI-based drug discovery if it successfully integrates these functions into its Claude platform.
